http://investor.cyclacel.com/releases.cfm?sh_auth=0.0.0.ad1dcb691ef81696c0c02ea27e385165Cyclacel Pharmaceuticals, Inc. - All Press Releasesen-usShareholder.com RSS Feedhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=766346Tue, 21 May 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=766346Cyclacel Pharmaceuticals Announces Closing of Underwritten Offeringhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=765451Thu, 16 May 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=765451Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offeringhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=765172Wed, 15 May 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=765172Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stockhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=764347Mon, 13 May 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=764347Cyclacel Reports First Quarter 2013 Financial Resultshttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=763840Fri, 10 May 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=763840Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Resultshttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=760331Tue, 30 Apr 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=760331Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDShttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=758347Tue, 23 Apr 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=758347Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conferencehttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=755324Tue, 09 Apr 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=755324Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACRhttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=754833Mon, 08 Apr 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=754833AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugshttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=754236Thu, 04 Apr 2013 13:30:00 GMThttp://investor.cyclacel.com/releasedetail.cfm?ReleaseID=754236Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation